Capital Asset Advisory Services LLC Purchases Shares of 1,118 Moderna, Inc. (NASDAQ:MRNA)

Capital Asset Advisory Services LLC acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,118 shares of the company’s stock, valued at approximately $117,000.

Several other institutional investors have also recently modified their holdings of MRNA. Black Swift Group LLC purchased a new position in shares of Moderna during the fourth quarter valued at about $26,000. Catalyst Capital Advisors LLC purchased a new position in Moderna in the fourth quarter worth about $29,000. Clearview Wealth Advisors LLC purchased a new position in Moderna in the fourth quarter worth about $32,000. Jeppson Wealth Management LLC purchased a new position in Moderna in the third quarter worth about $33,000. Finally, Lindbrook Capital LLC grew its position in Moderna by 81.1% in the fourth quarter. Lindbrook Capital LLC now owns 335 shares of the company’s stock worth $35,000 after acquiring an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 51.21% of the company’s stock.

Shares of NASDAQ:MRNA opened at $131.47 on Thursday. The company has a market capitalization of $52.66 billion, a price-to-earnings ratio of -81.15, a price-to-earnings-growth ratio of 0.53 and a beta of 1.73. Moderna, Inc. has a 52 week low of $31.32 and a 52 week high of $189.26. The company has a quick ratio of 2.43, a current ratio of 2.43 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average of $142.99 and a 200 day moving average of $120.18.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.44). Moderna had a negative return on equity of 28.11% and a negative net margin of 242.73%. The business had revenue of $570.80 million during the quarter, compared to the consensus estimate of $279.41 million. During the same period last year, the firm earned ($0.37) EPS. The business’s quarterly revenue was up 3948.2% on a year-over-year basis. On average, sell-side analysts expect that Moderna, Inc. will post -1.5 EPS for the current year.

In other Moderna news, insider Tal Zvi Zaks sold 5,000 shares of Moderna stock in a transaction on Monday, April 5th. The shares were sold at an average price of $129.71, for a total value of $648,550.00. Following the transaction, the insider now directly owns 5,000 shares of the company’s stock, valued at $648,550. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephane Bancel sold 11,046 shares of Moderna stock in a transaction on Friday, January 8th. The stock was sold at an average price of $114.02, for a total transaction of $1,259,464.92. Following the completion of the transaction, the chief executive officer now directly owns 6,503,868 shares in the company, valued at $741,571,029.36. The disclosure for this sale can be found here. Insiders sold 5,667,766 shares of company stock worth $824,359,096 over the last ninety days. Corporate insiders own 29.20% of the company’s stock.

MRNA has been the subject of several recent research reports. Oppenheimer lifted their price target on Moderna from $178.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, February 1st. Brookline Capital Management lifted their price target on Moderna from $180.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, March 4th. The Goldman Sachs Group reiterated a “buy” rating and issued a $139.00 price target on shares of Moderna in a research report on Friday, December 11th. Morgan Stanley dropped their price target on Moderna from $215.00 to $201.00 and set an “equal weight” rating for the company in a research report on Thursday, March 4th. Finally, Barclays lifted their price target on shares of Moderna from $169.00 to $178.00 in a research note on Friday, February 26th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. Moderna has an average rating of “Hold” and a consensus target price of $150.56.

Moderna Company Profile

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.

Read More: What is required to own or exchange cryptocurrency?

Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA).

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.